Eli Lilly and Company
LLY
$1,189.41
-$44.25-3.59%
NYSE
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -4.07% | 11.42% | 18.90% | -1.39% | 105.18% |
| Total Depreciation and Amortization | 4.91% | -13.10% | 24.62% | -1.67% | 3.24% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 510.90% | -179.64% | -120.61% | 299.65% | -143.64% |
| Change in Net Operating Assets | 59.74% | 54.71% | -404.10% | 153.39% | 32.73% |
| Cash from Operations | 100.45% | 65.38% | -63.51% | 186.23% | 85.29% |
| Capital Expenditure | -26.10% | 8.67% | -21.99% | -23.02% | -12.38% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -726.75% | -848.03% | 79.69% | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -598.50% | -269.70% | 58.35% | -152.19% | 92.57% |
| Cash from Investing | -293.16% | -39.75% | 6.05% | -62.63% | 45.30% |
| Total Debt Issued | 601.41% | 887,600.00% | -100.00% | -- | -100.00% |
| Total Debt Repaid | -16.40% | -249,900.00% | 99.99% | -595.96% | 144.62% |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | 32.05% | -56.26% | -112.92% | -2.33% | 42.33% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | 0.13% | -15.05% | -0.02% | 0.13% | -0.07% |
| Other Financing Activities | 99.32% | -2,254.58% | 16.89% | 2.58% | 95.48% |
| Cash from Financing | 342.82% | -20.54% | -642.15% | 142.65% | -190.22% |
| Foreign Exchange rate Adjustments | -177.61% | 199.85% | -311.67% | -88.47% | 108.33% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 284.69% | 21.30% | -139.33% | 2,167.14% | 261.71% |